| Literature DB >> 27815387 |
Ka-Wing Fong1, Jonathan C Zhao1, Jung Kim1, Shangze Li1, Yeqing A Yang1, Bing Song1, Laure Rittie2, Ming Hu3, Ximing Yang4,5, Bernard Perbal6, Jindan Yu7,5.
Abstract
The lethal phenotype of castration-resistant prostate cancer (CRPC) is generally caused by augmented signaling from the androgen receptor (AR). Here, we report that the AR-repressed gene CCN3/NOV inhibits AR signaling and acts in a negative feedback loop to block AR function. Mechanistically, a cytoplasmic form of CCN3 interacted with the AR N-terminal domain to sequester AR in the cytoplasm of prostate cancer cells, thereby reducing AR transcriptional activity and inhibiting cell growth. However, constitutive repression of CCN3 by the Polycomb group protein EZH2 disrupted this negative feedback loop in both CRPC and enzalutamide-resistant prostate cancer cells. Notably, restoring CCN3 was sufficient to effectively reduce CPRC cell proliferation in vitro and to abolish xenograft tumor growth in vivo Taken together, our findings establish CCN3 as a pivotal regulator of AR signaling and prostate cancer progression and suggest a functional intersection between Polycomb and AR signaling in CRPC. Cancer Res; 77(2); 412-22. ©2016 AACR. ©2016 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27815387 PMCID: PMC5243151 DOI: 10.1158/0008-5472.CAN-16-1949
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701